Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

261
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
261
Hepatic Portal System01:21

Hepatic Portal System

5.6K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.6K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

219
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
219
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

542
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
542
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

305
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
305
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

2.7K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Greening clubs- the role of sport in Ireland's approach to local climate action.

Frontiers in sports and active living·2026
Same author

Brief Report: Improving Lung Cancer Screening Rates: A Pilot Program for Low-Dose CT Implementation in a Community Cancer Center.

Clinical lung cancer·2026
Same author

HSR26-196: Experience With Pertuzumab-Based Neoadjuvant Therapy in HER2-Positive Breast Cancer: Treatment Patterns, Discontinuation, and Residual Disease Outcomes.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

HSR26-196: Experience With Pertuzumab-Based Neoadjuvant Therapy in HER2-Positive Breast Cancer: Treatment Patterns, Discontinuation, and Residual Disease Outcomes.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Comparative Efficacy and Safety of Non-Clotting Factor Prophylaxis Versus. on-Demand Therapy in Hemophilia: A Meta-Analysis of Randomized Controlled Trials.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same author

Performance of multiple multi-cancer detection tests using a large independent reference set (Alliance A212102).

Journal of the National Cancer Institute·2026

Related Experiment Video

Updated: Jan 23, 2026

Bacterial Cell Culture at the Single-cell Level Inside Giant Vesicles
07:33

Bacterial Cell Culture at the Single-cell Level Inside Giant Vesicles

Published on: April 30, 2019

7.5K

CLL associated giant cell hepatitis

Nikhila Kethireddy1, Evan Boyle1, Meredith Haley1

  • 1University of Connecticut, United States.

Leukemia Research
|June 7, 2019
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Synthesis of Compound Giant Unilamellar Vesicles: A Biomimetic Model of Nucleate Cells
10:10

Synthesis of Compound Giant Unilamellar Vesicles: A Biomimetic Model of Nucleate Cells

Published on: July 3, 2025

1.0K

Related Experiment Videos

Last Updated: Jan 23, 2026

Bacterial Cell Culture at the Single-cell Level Inside Giant Vesicles
07:33

Bacterial Cell Culture at the Single-cell Level Inside Giant Vesicles

Published on: April 30, 2019

7.5K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Synthesis of Compound Giant Unilamellar Vesicles: A Biomimetic Model of Nucleate Cells
10:10

Synthesis of Compound Giant Unilamellar Vesicles: A Biomimetic Model of Nucleate Cells

Published on: July 3, 2025

1.0K